Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement

Tae Ryong Chung, Jie-Hyun Kim, Ik Jae Lee, Yeona Cho, Jun Won Kim, Chang Geol Lee, Da Hyun Jung, Jae Jun Park, Young Hoon Youn, HyoJin Park

Research output: Contribution to journalArticle

Abstract

Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC)staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5%)of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7%)had supraclavicular lymph node metastasis and 10 (32.3%)had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004)and multivariate (p = 0.011)analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8% vs. 41.2%). Conclusions: M1a node involvement should be differentiated from regional node involvement.

Original languageEnglish
JournalDigestive and Liver Disease
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Carcinoma
Survival
Chemoradiotherapy
Joints
Lymph Nodes
Neoplasm Metastasis
Neoplasm Staging
Abdomen
Disease-Free Survival
Survival Rate
Recurrence
Esophageal Squamous Cell Carcinoma
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Chung, Tae Ryong ; Kim, Jie-Hyun ; Lee, Ik Jae ; Cho, Yeona ; Kim, Jun Won ; Lee, Chang Geol ; Jung, Da Hyun ; Park, Jae Jun ; Youn, Young Hoon ; Park, HyoJin. / Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement. In: Digestive and Liver Disease. 2019.
@article{adbfb6de24e54b19952952ccd2a84632,
title = "Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement",
abstract = "Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC)staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5{\%})of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7{\%})had supraclavicular lymph node metastasis and 10 (32.3{\%})had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004)and multivariate (p = 0.011)analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8{\%} vs. 41.2{\%}). Conclusions: M1a node involvement should be differentiated from regional node involvement.",
author = "Chung, {Tae Ryong} and Jie-Hyun Kim and Lee, {Ik Jae} and Yeona Cho and Kim, {Jun Won} and Lee, {Chang Geol} and Jung, {Da Hyun} and Park, {Jae Jun} and Youn, {Young Hoon} and HyoJin Park",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.dld.2019.05.014",
language = "English",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",

}

Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement. / Chung, Tae Ryong; Kim, Jie-Hyun; Lee, Ik Jae; Cho, Yeona; Kim, Jun Won; Lee, Chang Geol; Jung, Da Hyun; Park, Jae Jun; Youn, Young Hoon; Park, HyoJin.

In: Digestive and Liver Disease, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Different prognosis of patients with esophageal carcinoma with M1a and regional node involvement

AU - Chung, Tae Ryong

AU - Kim, Jie-Hyun

AU - Lee, Ik Jae

AU - Cho, Yeona

AU - Kim, Jun Won

AU - Lee, Chang Geol

AU - Jung, Da Hyun

AU - Park, Jae Jun

AU - Youn, Young Hoon

AU - Park, HyoJin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC)staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5%)of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7%)had supraclavicular lymph node metastasis and 10 (32.3%)had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004)and multivariate (p = 0.011)analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8% vs. 41.2%). Conclusions: M1a node involvement should be differentiated from regional node involvement.

AB - Background and purpose: Based on the 6th edition of the American Joint Commission on Cancer (AJCC)staging system for esophageal squamous cell carcinoma (ESCC), M1a node involvement was classified as regional node involvement in the revised 7th/8th edition. However, the clinical significance of M1a node involvement is unclear. Thus, we analyzed the prognostic value of M1a node involvement in patients with ESCC after definitive concurrent chemoradiotherapy (CCRT). Materials and methods: In total, 188 patients with ESCC had M0 disease according to the 7th/8th edition AJCC. We reclassified 31 (16.5%)of these patients as having M1a disease according to the 6th edition. After definitive CCRT, we compared baseline characteristics between the two groups and analyzed the rates of responders and recurrence. Finally, we compared prognoses according to overall survival (OS), disease-specific OS, and disease-free survival (DFS). Results: Among 31 patients reclassified to have M1a disease, 21 (67.7%)had supraclavicular lymph node metastasis and 10 (32.3%)had celiac lymph node metastasis. The number of responders was significantly lower for M1a disease based on univariate (p = 0.004)and multivariate (p = 0.011)analyses. Significantly lower survival rates were observed in individuals with M1a disease (median OS, 16.4 vs. 42.7 months; 5-year OS, 10.8% vs. 41.2%). Conclusions: M1a node involvement should be differentiated from regional node involvement.

UR - http://www.scopus.com/inward/record.url?scp=85066450586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066450586&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2019.05.014

DO - 10.1016/j.dld.2019.05.014

M3 - Article

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -